NXSTAGE REPORTS SECOND QUARTER FINANCIAL RESULTS AND RAISES FULL-YEAR REVENUE GUIDANCE
| |
| • | Revenue Increases to $92.2 million, up 15% from Q2'15 |
| |
| • | Home Revenue Increases to $51.1 million, up 14% from Q2'15 |
•Operating Income from Products Business Increases to $5.0 million
| |
| • | Full-Year Revenue Guidance Increases to $360 to $365 million |
| |
| • | Company Launches First of Many NxGen Features and Capabilities |
LAWRENCE, Mass., August 4, 2016, --NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported second quarter revenue above the top end of its guidance.
Total revenue for the second quarter of 2016 increased 15 percent to $92.2 million, compared with revenue of $80.3 million for the second quarter of 2015. The Company's revenue guidance range for the second quarter was $89.0 million to $91.0 million.
The Company's revenue performance was driven by the Products Business, and more specifically, outperformance in NxStage's largest segment, System One, which consists of its Home and Critical Care markets. Home revenue increased 14 percent to $51.1 million for the second quarter of 2016 compared with revenue of $44.8 million for the second quarter of 2015. Critical Care revenue increased 28 percent to $18.7 million for the second quarter of 2016 compared with revenue of $14.6 million for the second quarter of 2015.
Net loss attributable to NxStage Medical, Inc.'s stockholders improved to $1.7 million for the second quarter of 2016 compared with a net loss of $5.3 million for the second quarter of 2015 and included $5.0 million of income from operations from the Products Business.
"We delivered another strong quarter of growth and improving profitability. Looking ahead, we believe we are well positioned with tremendous growth opportunities which include an impressive stream of system launches expected over the next three years: our next generation hemodialysis system, our peritoneal dialysis system and our next generation critical care system," stated Jeffrey H. Burbank, Founder and CEO of NxStage.
The Company also announced that it launched enhanced priming features, the first of many upcoming capabilities of its next generation hemodialysis system. "The NxStage team is thrilled to provide patients and customers with access to new enhanced priming features that deliver on our promise of improved ease of use and reduced set-up time. In addition, these features are compatible with current generation System Ones, which means patients and customers can easily access them today," stated Burbank.
Guidance:
The Company now expects full-year revenue for 2016 to be in the range of $360 to $365 million, versus its previously increased guidance for revenue to be at the high end of its range of $355 to $360 million, reflecting Critical Care's outperformance during the quarter. The Company now expects its net loss for the full-year to be at the better end of its guidance range of $7 to $12 million.
For the third quarter of 2016, the Company expects revenue to be in the range of $89 to $91 million, which reflects expectations for lower revenue from the Company's In-Center segment as previously disclosed earlier this year. The Company also expects a net loss in the range of $1 to $3 million. The
Company's net loss guidance reflects expectations for continued operating income from the Products Business offset by the Company's continued investment in NxStage Kidney Care.
Conference Call:
NxStage will also host a conference call today, Thursday, August 4, 2016, at 9:00 a.m. Eastern Time to discuss its second quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international). The call will also be webcast LIVE and can be accessed via the investor relations section of the Company’s website at http://ir.nxstage.com.
A replay of the conference call will be available two hours after the completion of the call through August 11, 2016. To access the replay, dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 44443371. An online archive of the conference call can be accessed via the investor relations section of the Company’s website at http://ir.nxstage.com.
About NxStage
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage has also established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's website at http://www.nxstage.com and www.nxstagekidneycare.com.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and simplify alternative site care. The System One is also used to provide a range of flexible therapy options in more traditional care settings such as hospitals and dialysis centers. Its safety and efficacy have been demonstrated by experience with more than 13 million treatments with thousands of patients around the world.http://www.nxstage.com/.
Forward-Looking Statements
This release contains forward-looking statements concerning our business, operations and financial condition. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, market opportunities, timing of our new product launches, and our financial guidance for 2016 and beyond, including anticipated revenues and net loss. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products domestically and internationally, growth in home and/or
more frequent hemodialysis, regulatory approvals, competition, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and more frequent hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, including in response to NxStage Kidney Care, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.
In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.
|
|
| Contact: |
| Kristen K. Sheppard, Esq. |
| VP, Investor Relations |
| ksheppard@nxstage.com |
NxStage Medical, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands, except per share data)
(unaudited)
|
| | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| | 2016 | | 2015 | | 2016 | | 2015 |
| | | | | | | | |
| Revenues | $ | 92,207 |
| | $ | 80,316 |
| | $ | 181,414 |
| | $ | 159,798 |
|
| Cost of revenues | 53,784 |
| | 49,452 |
| | 106,474 |
| | 98,808 |
|
| Gross profit | 38,423 |
| | 30,864 |
| | 74,940 |
| | 60,990 |
|
| Operating expenses: | | | | | | | |
| Selling and marketing | 16,116 |
| | 14,518 |
| | 31,370 |
| | 29,066 |
|
| Research and development | 7,961 |
| | 6,622 |
| | 15,115 |
| | 12,496 |
|
| Distribution | 7,015 |
| | 6,255 |
| | 14,068 |
| | 12,626 |
|
| General and administrative | 8,511 |
| | 8,585 |
| | 16,542 |
| | 17,497 |
|
| Total operating expenses | 39,603 |
| | 35,980 |
| | 77,095 |
| | 71,685 |
|
| Loss from operations | (1,180 | ) | | (5,116 | ) | | (2,155 | ) | | (10,695 | ) |
| Other income (expense): | | | | | | | |
| Interest expense, net | (288 | ) | | (242 | ) | | (529 | ) | | (483 | ) |
| Other (expense) income, net | (409 | ) | | 37 |
| | (641 | ) | | 301 |
|
| Total other expense | (697 | ) | | (205 | ) | | (1,170 | ) | | (182 | ) |
| Net loss before income taxes | (1,877 | ) | | (5,321 | ) | | (3,325 | ) | | (10,877 | ) |
| Provision for income taxes | 348 |
| | 273 |
| | 683 |
| | 580 |
|
| Net loss | (2,225 | ) | | (5,594 | ) | | (4,008 | ) | | (11,457 | ) |
| Less: Net loss attributable to noncontrolling interests | (493 | ) | | (267 | ) | | (1,000 | ) | | (472 | ) |
| Net loss attributable to stockholders of NxStage Medical, Inc. | $ | (1,732 | ) | | $ | (5,327 | ) | | $ | (3,008 | ) | | $ | (10,985 | ) |
| Net loss per share, basic and diluted | $ | (0.03 | ) | | $ | (0.08 | ) | | $ | (0.05 | ) | | $ | (0.17 | ) |
| Weighted-average shares outstanding, basic and diluted | 64,428 |
| | 63,288 |
| | 64,302 |
| | 63,059 |
|
| Other comprehensive loss, net of tax | (1,280 | ) | | (154 | ) | | (219 | ) | | (930 | ) |
| Total comprehensive loss | (3,505 | ) | | (5,748 | ) | | (4,227 | ) | | (12,387 | ) |
| Less: Comprehensive loss attributable to noncontrolling interests | (493 | ) | | (267 | ) | | (1,000 | ) | | (472 | ) |
| Total comprehensive loss attributable to stockholders of NxStage Medical, Inc. | $ | (3,012 | ) | | $ | (5,481 | ) | | $ | (3,227 | ) | | $ | (11,915 | ) |
NxStage Medical, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)
|
| | | | | | | |
| | June 30, | | December 31, |
| | 2016 | | 2015 |
| | | | |
| ASSETS | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ | 58,459 |
| | $ | 59,065 |
|
| Accounts receivable, net | 30,092 |
| | 25,195 |
|
| Inventory | 41,309 |
| | 38,391 |
|
| Prepaid expenses and other current assets | 5,921 |
| | 6,254 |
|
| Total current assets | 135,781 |
| | 128,905 |
|
| Property and equipment, net | 66,374 |
| | 66,711 |
|
| Field equipment, net | 20,978 |
| | 20,744 |
|
| Deferred cost of revenues | 34,065 |
| | 33,068 |
|
| Intangible assets, net | 10,714 |
| | 11,744 |
|
| Goodwill | 42,710 |
| | 42,710 |
|
| Other assets | 3,074 |
| | 2,992 |
|
| Total assets | $ | 313,696 |
| | $ | 306,874 |
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |
| Current liabilities: | | | |
| Accounts payable | $ | 13,583 |
| | $ | 10,767 |
|
| Accrued expenses | 26,616 |
| | 27,266 |
|
| Current portion of long-term debt | 324 |
| | 315 |
|
| Other current liabilities | 4,452 |
| | 4,394 |
|
| Total current liabilities | 44,975 |
| | 42,742 |
|
| Deferred revenues | 52,280 |
| | 51,362 |
|
| Long-term debt | 1,602 |
| | 1,664 |
|
| Other long-term liabilities | 16,911 |
| | 17,367 |
|
| Total liabilities | 115,768 |
| | 113,135 |
|
| Commitments and contingencies | | | |
| Noncontrolling interests subject to put provisions | 168 |
| | 219 |
|
| Stockholders’ equity: | | | |
| Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2016 and December 31, 2015 | — |
| | — |
|
| Common stock: par value $0.001, 100,000,000 shares authorized; 65,443,862 and 64,873,038 shares issued as of June 30, 2016 and December 31, 2015, respectively | 65 |
| | 64 |
|
| Additional paid-in capital | 621,395 |
| | 612,487 |
|
| Accumulated deficit | (405,838 | ) | | (402,830 | ) |
| Accumulated other comprehensive loss | (4,250 | ) | | (4,031 | ) |
| Treasury stock, at cost: 901,013 and 822,059 shares as of June 30, 2016 and December 31, 2015, respectively | (15,334 | ) | | (13,864 | ) |
| Total NxStage Medical, Inc. stockholders' equity | 196,038 |
| | 191,826 |
|
| Noncontrolling interests not subject to put provisions | 1,722 |
| | 1,694 |
|
| Total stockholders' equity | 197,760 |
| | 193,520 |
|
| Total liabilities and stockholders’ equity | $ | 313,696 |
| | $ | 306,874 |
|
| | | | |
NxStage Medical, Inc.
Cash Flows from Operating Activities
(in thousands)
(unaudited)
|
| | | | | | | |
| | Six Months Ended June 30, |
| | 2016 | | 2015 |
| | | | |
| Cash flows from operating activities: | | | |
| Net loss | $ | (4,008 | ) | | $ | (11,457 | ) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | |
| Depreciation and amortization | 15,649 |
| | 15,473 |
|
| Stock-based compensation | 5,394 |
| | 6,590 |
|
| Other | (561 | ) | | 813 |
|
| Changes in operating assets and liabilities: | | | |
| Accounts receivable | (4,980 | ) | | (2,315 | ) |
| Inventory | (12,533 | ) | | (8,023 | ) |
| Prepaid expenses and other assets | 150 |
| | 169 |
|
| Accounts payable | 2,785 |
| | (641 | ) |
| Accrued expenses and other liabilities | 276 |
| | (2,036 | ) |
| Deferred revenues | 991 |
| | (957 | ) |
| Net cash provided by (used in) operating activities | $ | 3,163 |
| | $ | (2,384 | ) |
NxStage Medical, Inc.
Revenues by Segment
(in thousands)
(unaudited)
|
| | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| | 2016 | | 2015 | | 2016 | | 2015 |
| System One segment | | | | | | | |
| Home | $ | 51,102 |
| | $ | 44,789 |
| | $ | 100,638 |
| | $ | 88,287 |
|
| Critical Care | 18,745 |
| | 14,631 |
| | 38,512 |
| | 30,713 |
|
| Total System One segment | 69,847 |
| | 59,420 |
| | 139,150 |
| | 119,000 |
|
| In-Center segment | 16,731 |
| | 18,563 |
| | 33,497 |
| | 36,430 |
|
| Other | 3,408 |
| | 1,857 |
| | 5,589 |
| | 3,704 |
|
| Products subtotal | 89,986 |
| | 79,840 |
| | 178,236 |
| | 159,134 |
|
| Services segment | 4,114 |
| | 1,144 |
| | 6,801 |
| | 1,814 |
|
| Elimination of intersegment revenues | (1,893 | ) | | (668 | ) | | (3,623 | ) | | (1,150 | ) |
| Total | $ | 92,207 |
| | $ | 80,316 |
| | $ | 181,414 |
| | $ | 159,798 |
|
NxStage Medical, Inc.
Segment Financial Performance
(in thousands)
(unaudited)
|
| | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| | 2016 | | 2015 | | 2016 | | 2015 |
| Products Business (System One Segment, In-Center Segment & Other) | | | | | | | |
| Revenues | $ | 89,986 |
| | $ | 79,840 |
| | $ | 178,236 |
| | $ | 159,134 |
|
| Gross profit | $ | 42,097 |
| | $ | 34,781 |
| | $ | 83,433 |
| | $ | 68,487 |
|
| Gross margin percentage | 47 | % | | 44 | % | | 47 | % | | 43 | % |
| Income from operations | $ | 4,989 |
| | $ | 955 |
| | $ | 11,205 |
| | $ | 1,158 |
|
| Services | | | | | | | |
| Revenues | $ | 4,114 |
| | $ | 1,144 |
| | $ | 6,801 |
| | $ | 1,814 |
|
| Gross profit | $ | (3,454 | ) | | $ | (3,917 | ) | | $ | (8,103 | ) | | $ | (7,497 | ) |
| Gross margin percentage | n/a |
| | n/a |
| | n/a |
| | n/a |
|
| Loss from operations | $ | (5,949 | ) | | $ | (6,071 | ) | | $ | (12,970 | ) | | $ | (11,853 | ) |
| Eliminations | | | | | | | |
| Elimination of intersegment revenues | $ | (1,893 | ) | | $ | (668 | ) | | $ | (3,623 | ) | | $ | (1,150 | ) |
| Elimination of intersegment gross profit | $ | (220 | ) | | $ | — |
| | $ | (390 | ) | | $ | — |
|
| Total Company | | | | | | | |
| Revenues | $ | 92,207 |
| | $ | 80,316 |
| | $ | 181,414 |
| | $ | 159,798 |
|
| Gross profit | $ | 38,423 |
| | $ | 30,864 |
| | $ | 74,940 |
| | $ | 60,990 |
|
| Gross margin percentage | 42 | % | | 38 | % | | 41 | % | | 38 | % |
| Loss from operations | $ | (1,180 | ) | | $ | (5,116 | ) | | $ | (2,155 | ) | | $ | (10,695 | ) |
